These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12416480)

  • 1. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 2. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 3. New drugs to treat irritable bowel syndrome being tested.
    Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
    [No Abstract]   [Full Text] [Related]  

  • 4. Irritable bowel syndrome. A poorly understood disorder.
    Lewis C
    FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885
    [No Abstract]   [Full Text] [Related]  

  • 5. [Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].
    Hollerbach S; Elsenbruch S; Enck P
    Dtsch Med Wochenschr; 2001 Apr; 126(16):472-8. PubMed ID: 11360454
    [No Abstract]   [Full Text] [Related]  

  • 6. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 7. Zelnorm: new treatment available for women with IBS.
    Nursing; 2002 Oct; 32(10):24, 26. PubMed ID: 12400584
    [No Abstract]   [Full Text] [Related]  

  • 8. Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
    Olden KW
    Cleve Clin J Med; 2003 Jun; 70 Suppl 2():S3-7. PubMed ID: 12825862
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves restricted marketing of Lotronex.
    FDA Consum; 2002; 36(4):4. PubMed ID: 12184306
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA advisory panels recommend Lotronex be put back on market.
    Charatan F
    BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    Schiller LR; Johnson DA
    Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lotronex and the FDA: a fatal erosion of integrity.
    Horton R
    Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636
    [No Abstract]   [Full Text] [Related]  

  • 13. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
    Palmer JB
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drug for irritable bowel syndrome].
    Hennemann A
    Med Monatsschr Pharm; 2001 Apr; 24(4):106-8. PubMed ID: 11338633
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
    Avigan M; Justice R; Mackey AC; Nair N
    Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
    [No Abstract]   [Full Text] [Related]  

  • 17. A pill turned bitter. How a quest for a blockbuster drug went fatally wrong.
    Shapiro JP
    US News World Rep; 2000 Dec; 129(23):54-6. PubMed ID: 11126059
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on irritable bowel syndrome.
    Bergmann KA
    Postgrad Med J; 2003 Dec; 79(938):715. PubMed ID: 14707260
    [No Abstract]   [Full Text] [Related]  

  • 19. Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.
    Ehrenpreis ED
    Geriatrics; 2005 Jan; 60(1):25-8. PubMed ID: 15700946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approves one drug for irritable bowel syndrome but suspends another.
    Harv Womens Health Watch; 2008 Aug; 15(12):7. PubMed ID: 19115501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.